BR0313120A - bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation - Google Patents
bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparationInfo
- Publication number
- BR0313120A BR0313120A BRPI0313120-3A BR0313120A BR0313120A BR 0313120 A BR0313120 A BR 0313120A BR 0313120 A BR0313120 A BR 0313120A BR 0313120 A BR0313120 A BR 0313120A
- Authority
- BR
- Brazil
- Prior art keywords
- bleb
- neisserial
- vaccine
- los
- preparation
- Prior art date
Links
Abstract
PREPARAçõES DE BLEB E DE LOS, CEPA(S) NEISSERIAL/NEISSERIAIS, COMPOSIçãO IMUNOGêNICA OU VACINA, E, PROCESSOS DE FABRICAçãO DA VACINA DE PREPARAçãO DE BLEB NEISSERIAL E DE PRODUçãO DE UMA PREPARAçãO DE BLEB. A presente invenção refere-se ao campo das composições de vacina neisseriais, a sua fabricação, e ao uso de referidas composições na medicina. Mais particularmente, ela refere-se a processos para a preparação de cepas meningocócicas que são vantajosas para a produção de vacinas de vesícula de membrana externa (ou bleb) neisseriais, em particular meningocócicas. Descreve-se também processos e produtos de vacina vantajosos com base no uso de vacinas inéditas de vesícula de membrana externa (ou bleb) meningocócicas ou de subunidade de LOS que foram tornadas mais seguras e/ou mais efetivas para uso em sujeitos humanos. Em particular, descreve-se combinações de regulações para baixo de genes, como PorA <sym> OpA, PorA e OpC, OpA e OpC, e PorA e OpA e OpC. Alternativamente, ou adicionalmente, mostra-se que lgtB<sym> é uma mutação ótima para se utilizar de maneira efetiva e segura L3 e/ou L2 de LOS em composições de vacina de Neisseria. Descreve-se adicionalmente vacinas de bleb derivadas de mutantes meningocócicos com deficiência de polissacarídeo capsular e lgtB<sym>; e também processos vantajosos para fabricar preparações de bleb em que se pretende conservar LOS como um antígeno importante.PREPARATIONS OF BLEB AND LOS, NEISSERIAL / NEISSERIAL CUP (S), IMMUNOGENIC COMPOSITION OR VACCINE, AND PROCESSES FOR MANUFACTURING THE NEISSERIAL BLEB PREPARATION AND PRODUCTION OF A BLEB PREPARATION. The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of said compositions in medicine. More particularly, it relates to processes for the preparation of meningococcal strains that are advantageous for the production of neisserial outer membrane (or bleb), particularly meningococcal, bladder vaccines. Advantageous vaccine processes and products based on the use of unprecedented meningococcal outer membrane bleb (or bleb) or LOS subunit vaccines that have been made safer and / or more effective for use in human subjects. In particular, combinations of down-regulation of genes such as PorA <sym> OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC are described. Alternatively, or in addition, lgtB <sym> is shown to be an optimal mutation for effectively and safely using LOS and / or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from meningococcal mutants with capsular polysaccharide deficiency and lgtB <sym> are further described; and also advantageous processes for making bleb preparations in which LOS is to be preserved as an important antigen.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0218037A GB0218037D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GB0218036A GB0218036D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine |
GB0218035A GB0218035D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GB0218051A GB0218051D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GBGB0220199.4A GB0220199D0 (en) | 2002-08-30 | 2002-08-30 | Mutant protein and refolding method |
GBGB0220197.8A GB0220197D0 (en) | 2002-08-30 | 2002-08-30 | Refolding method |
GB0225531A GB0225531D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine |
GB0225524A GB0225524D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine composition |
GB0230168A GB0230168D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
GB0230164A GB0230164D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
PCT/EP2003/008568 WO2004014417A2 (en) | 2002-08-02 | 2003-07-31 | Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313120A true BR0313120A (en) | 2007-07-17 |
Family
ID=34705473
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313100-9A BR0313100A (en) | 2002-08-02 | 2003-07-31 | Immunogenic composition, isolated immunogenic composition, vaccine, method of treating or preventing gram-negative bacterial disease, use of the vaccine, genetically engineered gram-negative bacterial strain, method of preparing the immunogenic composition, method of preparing the vaccine, method of preparing a immunoglobulin for use in the prevention or treatment of neisserial infection, immunoglobulin preparation, pharmaceutical preparation, and use of pharmaceutical preparation |
BRPI0313120-3A BR0313120A (en) | 2002-08-02 | 2003-07-31 | bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313100-9A BR0313100A (en) | 2002-08-02 | 2003-07-31 | Immunogenic composition, isolated immunogenic composition, vaccine, method of treating or preventing gram-negative bacterial disease, use of the vaccine, genetically engineered gram-negative bacterial strain, method of preparing the immunogenic composition, method of preparing the vaccine, method of preparing a immunoglobulin for use in the prevention or treatment of neisserial infection, immunoglobulin preparation, pharmaceutical preparation, and use of pharmaceutical preparation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103007263A (en) |
BR (2) | BR0313100A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107602697B (en) * | 2017-08-29 | 2020-05-05 | 杭州医学院 | Serum for treating nasosinusitis caused by haemophilus influenzae and application of serum |
CN107722120B (en) * | 2017-08-29 | 2020-07-14 | 杭州医学院 | Serum for treating otitis media caused by haemophilus influenzae and application of serum |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2929348A1 (en) * | 1999-05-19 | 2000-11-30 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
-
2003
- 2003-07-31 BR BR0313100-9A patent/BR0313100A/en active Search and Examination
- 2003-07-31 CN CN2012102805434A patent/CN103007263A/en active Pending
- 2003-07-31 BR BRPI0313120-3A patent/BR0313120A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0313100A (en) | 2005-06-21 |
CN103007263A (en) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY149591A (en) | Vaccines comprising l2 and/or l3 los from neisseria | |
BR0107972A (en) | Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use | |
BRPI0409459A (en) | New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease | |
WO2007144316A3 (en) | Vaccine | |
PE20040562A1 (en) | VACCINES INVOLVING MIXTURES OF MULTIVALENT MENINGOCOCCAL STRAINS | |
HUP0400445A2 (en) | Novel vaccine composition | |
BRPI0210010B8 (en) | peptide immunogen, as well as composition and application comprising them | |
BR0015961A (en) | 85kda neisserial antigen | |
BR0212999A (en) | New Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease | |
EE200200507A (en) | Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing it, Preparation and Therapeutic Use of MVA | |
BR0010323A (en) | Immunogenic compositions, kit and method of making it for use in the immunization of a mammal | |
BR0207819A (en) | Protein, cytokine, mutated human il-13, polynucleotide, vector, host, pharmaceutical composition, use of a protein, methods for the treatment of il-13 mediated disease prophylaxis, and for the preparation of a protein | |
ZA200602246B (en) | Immunogenic HIV compositions and related methods | |
BRPI0516770A (en) | Vaccine and Protein Conjugates - Multivalent Meningococcal Polysaccharide Derivatives | |
BR0313120A (en) | bleb and de los preparations, neisserial / neisserial strain (s), immunogenic composition or vaccine, and, manufacturing processes of the neisserial bleb preparation vaccine and production of a bleb preparation | |
Karpenko et al. | Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine: Design, immunogenicity and toxicity studies | |
Klatt et al. | Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques | |
JP2019520090A (en) | Vaccine composition comprising attenuated mutant Zika virus | |
MX2010003220A (en) | Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon. | |
Van Den Dobbelsteen et al. | From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine | |
WO2021144478A8 (en) | Combination treatment for fumarate-related diseases | |
Andrieu et al. | A 30-year journey of trial and error towards a tolerogenic AIDS vaccine | |
CA2295316A1 (en) | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy | |
Harboe | Armauer Hansen-the man and his work | |
WO2005117956A3 (en) | Neisserial vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |